atrasentan has been researched along with bardoxolone methyl in 1 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (bardoxolone methyl) | Trials (bardoxolone methyl) | Recent Studies (post-2010) (bardoxolone methyl) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 237 | 18 | 186 |
| Protein | Taxonomy | atrasentan (IC50) | bardoxolone methyl (IC50) |
|---|---|---|---|
| Ghrelin O-acyltransferase | Mus musculus (house mouse) | 0.035 | |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 2.38 | |
| Ghrelin O-acyltransferase | Homo sapiens (human) | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breyer, MD; Susztak, K | 1 |
1 review(s) available for atrasentan and bardoxolone methyl
| Article | Year |
|---|---|
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |